CA3049183A1 - Treatment of pancreatic cancer - Google Patents
Treatment of pancreatic cancer Download PDFInfo
- Publication number
- CA3049183A1 CA3049183A1 CA3049183A CA3049183A CA3049183A1 CA 3049183 A1 CA3049183 A1 CA 3049183A1 CA 3049183 A CA3049183 A CA 3049183A CA 3049183 A CA3049183 A CA 3049183A CA 3049183 A1 CA3049183 A1 CA 3049183A1
- Authority
- CA
- Canada
- Prior art keywords
- refractory
- resistant
- gemcitabine
- paclitaxel
- liposomal formulation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/186—Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dispersion Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762442636P | 2017-01-05 | 2017-01-05 | |
| US62/442,636 | 2017-01-05 | ||
| PCT/CN2018/071312 WO2018127082A1 (en) | 2017-01-05 | 2018-01-04 | Treatment of pancreatic cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3049183A1 true CA3049183A1 (en) | 2018-07-12 |
Family
ID=62789060
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3049183A Pending CA3049183A1 (en) | 2017-01-05 | 2018-01-04 | Treatment of pancreatic cancer |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US20190380994A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3565530B1 (cg-RX-API-DMAC7.html) |
| JP (2) | JP2020504138A (cg-RX-API-DMAC7.html) |
| KR (2) | KR20190103304A (cg-RX-API-DMAC7.html) |
| CN (1) | CN110267650A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2018205544B2 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112019013983A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3049183A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL267613B2 (cg-RX-API-DMAC7.html) |
| MX (2) | MX2019008132A (cg-RX-API-DMAC7.html) |
| TW (1) | TWI852903B (cg-RX-API-DMAC7.html) |
| WO (1) | WO2018127082A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11040027B2 (en) | 2017-01-17 | 2021-06-22 | Heparegenix Gmbh | Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death |
| CN110974954B (zh) * | 2019-12-24 | 2021-03-16 | 珠海丽凡达生物技术有限公司 | 一种用于增强核酸疫苗免疫效果的脂质纳米颗粒及其制备方法 |
| EP4659741A1 (en) * | 2023-01-31 | 2025-12-10 | CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd. | Use of paclitaxel cationic liposome in treating tumors |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW197439B (cg-RX-API-DMAC7.html) | 1991-04-04 | 1993-01-01 | Ueno Pharmaceutics Applic Res Co Ltd | |
| US5283253A (en) | 1991-09-23 | 1994-02-01 | Florida State University | Furyl or thienyl carbonyl substituted taxanes and pharmaceutical compositions containing them |
| WO1993010076A1 (en) | 1991-11-22 | 1993-05-27 | The University Of Mississippi | Synthesis and optical resolution of the taxol side chain and related compounds |
| US5200534A (en) | 1992-03-13 | 1993-04-06 | University Of Florida | Process for the preparation of taxol and 10-deacetyltaxol |
| AU4242993A (en) | 1992-05-21 | 1993-12-13 | Penn State Research Foundation, The | Cultured (taxus) tissues as a source of taxol, related taxanes and other novel anti-tumor/anti-viral compounds |
| US5274137A (en) | 1992-06-23 | 1993-12-28 | Nicolaou K C | Intermediates for preparation of taxols |
| US5294637A (en) | 1992-07-01 | 1994-03-15 | Bristol-Myers Squibb Company | Fluoro taxols |
| US5202448A (en) | 1992-08-14 | 1993-04-13 | Napro Biotherapeutics, Inc. | Processes of converting taxanes into baccatin III |
| CA2100808A1 (en) | 1992-10-01 | 1994-04-02 | Vittorio Farina | Deoxy paclitaxels |
| FR2696463B1 (fr) | 1992-10-05 | 1994-11-25 | Rhone Poulenc Rorer Sa | Procédé d'obtention de la désacétyl-10 baccatine III. |
| FR2696464B1 (fr) | 1992-10-05 | 1994-11-10 | Rhone Poulenc Rorer Sa | Nouveau procédé d'estérification de la baccatine III et de la désacétyl-10 baccatine III. |
| FR2696458B1 (fr) | 1992-10-05 | 1994-11-10 | Rhone Poulenc Rorer Sa | Procédé de préparation de dérivés du taxane. |
| FR2696462B1 (fr) | 1992-10-05 | 1994-11-25 | Rhone Poulenc Rorer Sa | Procédé d'obtention de la désacétyl-10 baccatine III. |
| FR2696461B1 (fr) | 1992-10-05 | 1994-11-10 | Rhone Poulenc Rorer Sa | Nouveaux dérivés d'analogues du taxol, leur préparation et les compositions qui les contiennent. |
| US5279949A (en) | 1992-12-07 | 1994-01-18 | Board Of Trustees Operating Michigan State University | Process for the isolation and purification of taxol and taxanes from Taxus spp |
| US5415869A (en) | 1993-11-12 | 1995-05-16 | The Research Foundation Of State University Of New York | Taxol formulation |
| WO1998008833A1 (en) | 1996-08-26 | 1998-03-05 | Bristol-Myers Squibb Company | Sulfenamide taxane derivatives |
| WO1998022451A1 (en) | 1996-11-19 | 1998-05-28 | Daiichi Pharmaceutical Co., Ltd. | Taxol derivatives |
| US5977386A (en) | 1996-12-24 | 1999-11-02 | Bristol-Myers Squibb Company | 6-thio-substituted paclitaxels |
| US7288665B1 (en) | 1997-08-18 | 2007-10-30 | Florida State University | Process for selective derivatization of taxanes |
| JPH1192468A (ja) | 1997-09-17 | 1999-04-06 | Yakult Honsha Co Ltd | 新規なタキサン誘導体 |
| WO1999018113A1 (fr) | 1997-10-08 | 1999-04-15 | Bio Research Corporation Of Yokohama | Derives taxoides et leur procede de production |
| ES2331791T5 (es) | 2002-06-26 | 2016-01-21 | Medigene Ag | Método de producción de una preparación catiónica de liposomas que comprende un compuesto lipófilo |
| WO2005039533A1 (en) * | 2003-10-15 | 2005-05-06 | Medigene Ag | Method of administering cationic liposomes comprising an active drug |
| CA2601067A1 (en) * | 2005-05-04 | 2006-11-09 | Medigene Ag | Method of administering a cationic liposomal preparation comprising paclitaxel |
| CA2646156C (en) * | 2006-03-22 | 2016-05-24 | Medigene Ag | Treatment of triple receptor negative breast cancer |
| CN102946880A (zh) * | 2010-04-23 | 2013-02-27 | 尼基制药公司 | 治疗胰腺癌的方法 |
| TWI760319B (zh) * | 2015-12-30 | 2022-04-11 | 杏國新藥股份有限公司 | 乳癌治療 |
| AU2017324947A1 (en) * | 2016-09-06 | 2019-03-28 | Mayo Foundation For Medical Education And Research | Paclitaxel-albumin-binding agent compositions and methods for using and making the same |
-
2018
- 2018-01-03 TW TW107100183A patent/TWI852903B/zh active
- 2018-01-04 IL IL267613A patent/IL267613B2/en unknown
- 2018-01-04 US US16/475,524 patent/US20190380994A1/en not_active Abandoned
- 2018-01-04 EP EP18735805.6A patent/EP3565530B1/en active Active
- 2018-01-04 CA CA3049183A patent/CA3049183A1/en active Pending
- 2018-01-04 WO PCT/CN2018/071312 patent/WO2018127082A1/en not_active Ceased
- 2018-01-04 CN CN201880005488.3A patent/CN110267650A/zh active Pending
- 2018-01-04 JP JP2019536978A patent/JP2020504138A/ja active Pending
- 2018-01-04 KR KR1020197022857A patent/KR20190103304A/ko not_active Ceased
- 2018-01-04 MX MX2019008132A patent/MX2019008132A/es unknown
- 2018-01-04 BR BR112019013983A patent/BR112019013983A2/pt not_active Application Discontinuation
- 2018-01-04 KR KR1020247034557A patent/KR20240154694A/ko not_active Ceased
- 2018-01-04 AU AU2018205544A patent/AU2018205544B2/en active Active
-
2019
- 2019-07-04 MX MX2022005350A patent/MX2022005350A/es unknown
-
2022
- 2022-02-24 US US17/652,409 patent/US20230035723A1/en not_active Abandoned
- 2022-09-15 JP JP2022146962A patent/JP2022180464A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| BR112019013983A2 (pt) | 2020-04-28 |
| IL267613A (en) | 2019-08-29 |
| TWI852903B (zh) | 2024-08-21 |
| CN110267650A (zh) | 2019-09-20 |
| IL267613B2 (en) | 2024-11-01 |
| EP3565530B1 (en) | 2026-08-19 |
| MX2022005350A (es) | 2022-06-02 |
| EP3565530A1 (en) | 2019-11-13 |
| KR20240154694A (ko) | 2024-10-25 |
| US20190380994A1 (en) | 2019-12-19 |
| RU2019124441A (ru) | 2021-02-05 |
| JP2022180464A (ja) | 2022-12-06 |
| EP3565530A4 (en) | 2020-07-01 |
| TW201825087A (zh) | 2018-07-16 |
| US20230035723A1 (en) | 2023-02-02 |
| IL267613B1 (en) | 2024-07-01 |
| AU2018205544A1 (en) | 2019-06-27 |
| AU2018205544B2 (en) | 2024-02-29 |
| WO2018127082A1 (en) | 2018-07-12 |
| KR20190103304A (ko) | 2019-09-04 |
| RU2019124441A3 (cg-RX-API-DMAC7.html) | 2021-04-21 |
| JP2020504138A (ja) | 2020-02-06 |
| MX2019008132A (es) | 2019-09-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US9707204B2 (en) | Treatment of breast cancer | |
| US20220313608A1 (en) | Treatment of breast cancer | |
| US20230035723A1 (en) | Treatment of Pancreatic Cancer | |
| EP1896007A2 (en) | Method of administering a cationic liposomal preparation comprising paclitexel | |
| RU2792690C2 (ru) | Лечение рака поджелудочной железы | |
| HK1123229B (en) | Treatment of triple receptor negative breast cancer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20230103 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION Effective date: 20240731 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20241223 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 7TH ANNIV.) - STANDARD Year of fee payment: 7 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20241227 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20241227 Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20241227 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20250221 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20250221 |
|
| D15 | Examination report completed |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT Effective date: 20250326 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION Effective date: 20250610 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250611 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20250703 |